Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.33 |
| ▸ | CACNA1G | O43497 | 1/20 | 0.33 |
| ▸ | PTGFR | P43088 | 5/20 | 0.32 |
| ▸ | RAB9A | P51151 | 2/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.32 |
| ▸ | AAK1 | Q2M2I8 | 1/20 | 0.31 |
| ▸ | KCNN4 | O15554 | 2/20 | 0.31 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.30 |
| ▸ | HTR1A | P08908 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL957713 | 1.00 | HDAC6 (0.33) | HDAC6CACNA1GPTGFRRAB9AKMT2A | |
| SCHEMBL3641776 | 0.83 | FAAH (0.33) | CACNA1GPTGFRRAB9ASMN1; SMN2 | |
| SCHEMBL957712 | 0.80 | GAA (0.32) | RAB9ASMN1; SMN2 | |
| SCHEMBL3647417 | 0.77 | KCNN4 (0.38) | HDAC6RAB9AKMT2ASMN1; SMN2KCNN4 | |
| SCHEMBL957773 | 0.77 | KCNN4 (0.33) | HDAC6KMT2ASMN1; SMN2KCNN4 | |
| SCHEMBL957772 | 0.72 | ALDH1A1 (0.33) | CACNA1G | |
| SCHEMBL15368372 | 0.72 | ALDH1A1 (0.33) | CACNA1G | |
| SCHEMBL15355335 | 0.70 | PMP22 (0.32) | KMT2ASMN1; SMN2KCNN4 | |
| SCHEMBL15355336 | 0.70 | PMP22 (0.32) | KMT2ASMN1; SMN2KCNN4 | |
| SCHEMBL15355334 | 0.70 | PMP22 (0.32) | KMT2ASMN1; SMN2KCNN4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110015157-A1 | CYCLIC INHIBITORS OF 11BETA-HYDROXYSTEROID DEHYDROGENASE 1 | Vitae Pharmaceuticals ,Inc. | 2011-01-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110015157-A1 | CYCLIC INHIBITORS OF 11BETA-HYDROXYSTEROID DEHYDROGENASE 1 | HSD11B1, HSD11B2, HSD3B1 | HDAC6 1011/4885CACNA1G 3585/4885PTGFR 2323/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.